Profile of ipilimumab and its role in the treatment of metastatic melanoma
Open Access
- 1 December 2011
- journal article
- review article
- Published by Informa UK Limited in Drug Design, Development and Therapy
- Vol. 5, 489-95
- https://doi.org/10.2147/dddt.s10945
Abstract
Peer reviewed article authored by (Patel SP, Woodman SE). Read article or submit your manuscript for publishing.Keywords
This publication has 40 references indexed in Scilit:
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer ImmunotherapyClinical Cancer Research, 2011
- Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer—Preclinical Background: CTLA-4 and PD-1 BlockadeSeminars in Oncology, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma PatientsClinical Cancer Research, 2010
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsProceedings of the National Academy of Sciences of the United States of America, 2010
- Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative RegimensJournal of Clinical Oncology, 2008
- Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with VaccinesClinical Cancer Research, 2008
- CTLA-4: new insights into its biological function and use in tumor immunotherapyNature Immunology, 2002
- High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993Journal of Clinical Oncology, 1999
- Molecular Basis of T Cell Inactivation by CTLA-4Science, 1998